Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Compugen ( (CGEN) ) has shared an update.
On July 21, 2025, Compugen Ltd. announced the dosing of the first patient in a global trial for COM701, a potential first-in-class anti-PVRIG antibody, aimed at treating relapsed platinum sensitive ovarian cancer. The trial, supported by strong biological rationale and clinical data, seeks to address significant unmet medical needs and could potentially pave the way for COM701’s broader application in ovarian cancer treatment. An interim analysis is planned for the second half of 2026, which could inform future registration paths and combination therapy opportunities.
The most recent analyst rating on (CGEN) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Compugen stock, see the CGEN Stock Forecast page.
Spark’s Take on CGEN Stock
According to Spark, TipRanks’ AI Analyst, CGEN is a Neutral.
The overall stock score is influenced significantly by the company’s financial performance and technical analysis. While strategic partnerships and improved cash flow management are promising, ongoing profitability challenges and valuation concerns weigh on the stock’s attractiveness.
To see Spark’s full report on CGEN stock, click here.
More about Compugen
Compugen Ltd. is a clinical-stage therapeutic discovery and development company specializing in cancer immunotherapies. Utilizing its predictive AI/ML powered computational discovery platform, Compugen identifies new drug targets and biological pathways. The company has proprietary product candidates such as COM701, an anti-PVRIG antibody, and COM902, targeting TIGIT for solid tumors. Compugen is headquartered in Israel with offices in San Francisco, and its shares are listed on Nasdaq and the Tel Aviv Stock Exchange.
Average Trading Volume: 226,051
Technical Sentiment Signal: Strong Sell
Current Market Cap: $144M
See more data about CGEN stock on TipRanks’ Stock Analysis page.